Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is one of the top most undervalued biotech stocks to buy now. H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) on August 6, setting a price target of $70.00.
HRMY A close-up of a pharmaceutical drug bottle, showcasing the potential of the company's innovative therapies.
The analyst told investors that Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) has continuously advancing pipeline programs and has exhibited consistent commercial execution, suggesting resilient growth.
This holds especially true for its product WAKIX, which has shown solid revenue growth and expanded its prescriber base.
The analyst also reasoned that Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) has a solid financial position with reaffirmed revenue guidance and considerable cash reserves, positioning it to pursue and self-fund growth opportunities.
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is a commercial-stage pharmaceutical company that develops and commercializes therapies to treat neurological disorders.
Its product, WAKIX, is a molecule that increases histamine signaling in the brain by binding to H3 receptors. The company has one of the strongest pipelines for people with rare neurological diseases.
While we acknowledge the potential of HRMY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
